Adelaide Research & Scholarship: Search

Search

Results 21-30 of 36 (Search time: 0.004 seconds).

previous
1
2
3
4
next

Item hits:

Preview	Issue Date	Title	Author(s)
	2012	Intrathecal recombinant human 4-sulfatase reduces accumulation of glycosaminoglycans in dura of mucopolysaccharidosis VI cats	Auclair, D.; Finnie, J.; Walkley, S.; White, J.; Nielsen, T.; Fuller, M.; Cheng, A.; O'Neill, C.; Hopwood, J.
	2003	Prevalence of mucopolysaccharidosis type VI mutations in Siamese cats	Crawley, A.; Muntz, F.; Haskins, M.; Jones, B.; Hopwood, J.
	1998	Mild feline mucopolysaccharidosis type VI. Identification of an N-acetylgalactosamine-4-sulfatase mutation causing instability and increased specific activity	Yogalingam, G.; Hopwood, J.; Crawley, A.; Anson, D.
	1996	Enzyme replacement therapy in a feline model of Maroteaux-Lamy syndrome	Crawley, A.; Brooks, D.; Muller, V.; Petersen, B.; Isaac, E.; Bielicki, J.; King, B.; Boulter, C.; Moore, A.; Fazzalari, N.; Anson, D.; Byers, S.; Hopwood, J.
	1997	Enzyme replacement therapy from birth in a feline model of mucopolysaccharidosis type VI	Crawley, A.; Niedzielski, K.; Isaac, E.; Davey, R.; Byers, S.; Hopwood, J.
	1998	Two mutations within a feline mucopolysaccharidosis type VI colony cause three different clinical phenotypes	Crawley, A.; Yogalingam, G.; Muller, V.; Hopwood, J.
	2006	Intra-articular enzyme administration for joint disease in feline mucopolysaccharidosis VI: Enzyme dose and interval	Auclair, D.; Hein, L.; Hopwood, J.; Byers, S.
	2004	Monitoring dose response of enzyme replacement therapy in feline mucopolysaccharidosis type VI by tandem mass spectrometry	Crawley, A.; Ramsay, S.; Byers, S.; Hopwood, J.; Meikle, P.
	2000	Enzyme replacement therapy in a feline model of MPS VI: Modification of enzyme structure and dose frequency	Byers, S.; Crawley, A.; Brumfield, L.; Nuttall, J.; Hopwood, J.
	2005	Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human n-acetylgalactosamine 4-sulfatase	Harmatz, P.; Ketteridge, D.; Giugliani, R.; Guffon, N.; Teles, E.; Miranda, C.; Yu, Z.; Swiedler, S.; Hopwood, J.